Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Fabrice André , Eva Ciruelos , Gábor Rubovszky , Fabrice André , Eva Ciruelos , Gábor Rubovszky , Mario Campone , Sibylle Loibl , Hope S. Rugo , Hiroji Iwata , Pierfranco Conté , Ingrid A. Mayer , Bella Kaufman , Toshinari Yamashita , Yen‐Shen Lu , Kenichi Inoue , Masato Takahashi , Zsuzsanna Pápai , Anne-Sophie Longin , David Mills , Celine Wilke , Samit Hirawat , Dejan Juric
2019 New England Journal of Medicine 2,305 citations

Abstract

Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).

Keywords

Breast cancerHormone receptorHormoneHuman Epidermal Growth Factor Receptor 2Internal medicineCancer researchOncologyReceptorMedicineCancerEndocrinology

Affiliated Institutions

Related Publications

Publication Info

Year
2019
Type
article
Volume
380
Issue
20
Pages
1929-1940
Citations
2305
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2305
OpenAlex

Cite This

Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. (2019). Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine , 380 (20) , 1929-1940. https://doi.org/10.1056/nejmoa1813904

Identifiers

DOI
10.1056/nejmoa1813904